Clinical trialsCompany release

Aclaris begins Phase 2b trial of modzatinib in lichen planus

🇺🇸 Aclaris Therapeutics, Inc. (ACRS) · Mon 16 Nov 2026

The randomised, placebo-controlled study of the oral ITK/JAK3 inhibitor will enrol about 100 patients, starting with oral erosive disease, which holds FDA Fast Track status.

Aclaris Therapeutics announced on 16 November 2026 that it has started a Phase 2b trial of modzatinib (ATI-2138) in moderate-to-severe lichen planus. The study is randomised and placebo-controlled, and is planned to enrol about 100 patients.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Aclaris Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Aclaris Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →